Delivery Order 75N91019D00024-75N91020F00037
Award Date 9/25/20
Potential Completion Date 9/24/25
Potential Value $993K
Federal Agency
Ultimate Awardee
NAICS Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Cost Plus Fixed Fee
Place of Performance
Frederick, MD 21702, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This federal contract award to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc., is for the "Elaboration and Use of Syngenic Pre-Clinical Models for Cancer Drug Development" in support of the President's Department of Government Efficiency Cost Efficiency Initiative. The $9,972,144.00 cost-plus-fixed-fee delivery order contract has an ultimate completion date of September 15, 2026 and was awarded on September 16, 2021 by the National Cancer Institute, a civilian...
- The National Cancer Institute awarded an $8.19 million cost-plus-fixed-fee delivery order to Leidos Biomedical Research Inc. for the HCMI/CMDC Sequencing and HCMI Searchable Catalog (Moonshot) project, with performance through September 24, 2027. Work will be performed in Frederick, Maryland, where Leidos operates as a Federally Funded Research and Development Center (FFRDC) contractor for NCI and the National Institutes of Health. This project supports the NCI's broader cancer research...
- The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a cost-plus-fixed-fee delivery order contract worth up to $3,332,886.00 to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The contract is for the identification and delivery of clinical drug candidates, with a completion date of September 24, 2025. Leidos Biomedical Research Inc. is a Federally Funded Research and Development Center (FFRDC) that provides...
- This is a federal contract award made by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The contract, valued at $5,506,164.00, is for the identification and delivery of clinical drug candidates. It is a delivery order contract, with a cost-no-fee pricing type. The contract is not set aside and is part of Leidos Biomedical Research's role as a Federally Funded...
- This is a $67,013,032.00 cost-plus-fixed-fee delivery order contract awarded by the National Cancer Institute (NCI) to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The contract is to expand the NCI's data commons over a 5-year base period from September 2018 to September 2023, with a maximum potential period of performance through August 2027. Leidos Biomedical Research Inc. is a Federally Funded Research and Development Center (FFRDC) contractor for the NCI,...
- This is a delivery order contract awarded by the National Cancer Institute (NCI), a civilian agency, to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The contract is for "Comparative Oncology Clinical Trials" and is related to the President's Department of Government Efficiency Cost Efficiency Initiative. The contract has a ceiling value of $1,780,568.00 and a completion date of September 24, 2025. It is a cost-plus-fixed-fee contract type and was not set aside...
- The National Cancer Institute (NCI) awarded a delivery order valued at approximately $19.2 million to Leidos Biomedical Research Inc. on August 25, 2020, with an ultimate completion date of December 2, 2027. This cost-plus-fixed-fee contract is part of the FY20 Consolidated Facilities task order program and does not include a small business set-aside designation. The work will be performed at the Frederick National Laboratory for Cancer Research in Frederick, Maryland, where Leidos Biomedical...
- This is a federal contract award to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc., to serve as the National Cancer Institute's (NCI) Federally Funded Research and Development Center (FFRDC) contractor. The $6,289,947.00 cost-plus-fixed-fee contract, awarded on February 9, 2021, has a period of performance through November 13, 2025. Leidos Biomedical Research Inc. will provide a comprehensive range of biomedical research and facilities support services to the NCI,...
- Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. and Federally Funded Research and Development Center (FFRDC) contractor, received a delivery order valued at $637,460 from the National Cancer Institute (NCI) with an award date of July 8, 2024 and an ultimate completion date of March 6, 2026. The contract is structured as a cost-plus-fixed-fee delivery order with no set-aside designation, indicating competitive award based on the contractor's demonstrated capabilities. The...
- This is a federal contract award from the National Cancer Institute (NCI), a civilian agency, to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The contract supports the Center for Molecular Characterization (CMC) in providing support for projects related to the National Center for Advancing Translational Sciences (NCATS) Therapeutics for Rare and Neglected Diseases (TRND) program. The contract has a ceiling value of $9,459,207.00 and a period of performance through...